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There is an urgent need to identify therapeutics for the treatment of Coronavirus disease
2019 (COVID-19). Although different antivirals are given for the clinical management of
SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened
existing drugs approved for human use in a variety of diseases, to compare how they
counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. Among the
potential 72 antivirals tested herein that were previously proposed to inhibit SARS-CoV-2
infection, only 18% had an IC50 below 25 µM or 10
2 IU/ml. These included plitidepsin,
novel cathepsin inhibitors, nelfinavir mesylate hydrate, interferon 2-alpha, interferon-
gamma, fenofibrate, camostat along the well-known remdesivir and chloroquine
derivatives. Plitidepsin was the only clinically approved drug displaying nanomolar
efficacy. Four of these families, including novel cathepsin inhibitors, blocked viral entry
in a cell—type specific manner. Since the most effective antivirals usually combine
therapies that tackle the virus at different steps of infection, we also assessed several
drug combinations. Although no particular synergy was found, inhibitory combinations did
not reduce their antiviral activity. Thus, these combinations could decrease the potential
emergence of resistant viruses. Antivirals prioritized herein identify novel compounds and
their mode of action, while independently replicating the activity of a reduced proportion of
drugs which are mostly approved for clinical use. Combinations of these drugs should be
tested in animal models to inform the design of fast track clinical trials.
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INTRODUCTION
A novel betacoronavirus, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is causing a respiratory disease
pandemic that began in Wuhan, China, in November 2019, and
has now spread across the world (Chen et al., 2020b). To date,
remdesivir is the only approved antiviral drug for the specific
treatment of this coronavirus infectious disease 2019 or COVID-
19 (Beigel et al., 2020; Grein et al., 2020). However, several drugs
are being used in the frontline of clinical management of SARS-
CoV-2-infected individuals in hospitals all around the world, to
try to avoid the development of the COVID-19 associated
pneumonia, which can be fatal. By the end of December 2020,
almost 1.7 million people had died from COVID-19, and over 75
million cases have been reported (https://covid19.who.int).
Although different drug regimens are being applied to
hospitalized patients, no clinical study has evidenced their
efficacy yet. Under this scenario, initiatives launched by the
World Health Organization (WHO), such as the
SOLIDARITY study that has compared remdesivir,
hydroxychloroquine, ritonavir/lopinavir and ritonavir/lopinavir
plus ß-interferon regimes, have been of critical importance to
prioritize the use of the most active compounds (WHO, 2020).
Unfortunately, although remdesivir has proven efficacy in
randomized controlled trials (Beigel et al., 2020; Grein et al.,
2020), a recent update of the WHO clinical trial has failed to
detect any effect on overall mortality, initiation of ventilation and
duration of hospital stay with any of the antivirals tested (Pan,
2020). Thus, there is an urgent need to identify novel therapeutic
approaches for individuals with COVID-19 developing severe
disease and fatal outcomes.
In this report we present a prioritized list of effective
compounds with proven antiviral efficacy in vitro to halt
SARS-CoV-2 replication. Compounds were analyzed
depending on their expected mechanism of action, to identify
candidates tackling diverse steps of the viral life cycle. SARS-
CoV-2 entry requires viral binding and spike protein activation
via interaction with the cellular receptor ACE2 and the cellular
protease TMPRSS2 at the plasma membrane (Hoffmann et al.,
2020). Interference with either of these ligands has proven to
decrease SARS-CoV-2 infectivity (Monteil et al. 2020; Hoffmann
et al., 2020), and therefore, inhibitors targeting viral entry may
prove valuable. In addition, SARS-CoV-2 enters into the cells via
endocytosis and accumulates in endosomes where cellular
cathepsins can also prime the spike protein and favor viral
fusion upon cleavage (Simmons et al., 2005; Mingo et al.,
2015; Hoffmann et al., 2020), providing additional targets for
antiviral activity. Once SARS-CoV-2 fuses with cellular
membranes, it triggers viral RNA release into the cytoplasm,
where polyproteins are translated and cleaved by proteases (Song
et al., 2019). This leads to the formation of an RNA
replicase—transcriptase complex driving the production of
several negative—stranded RNA via both replication and
transcription (Song et al., 2019). Numerous negative-stranded
RNAs transcribe into messenger RNA genomes, allowing for the
translation of viral nucleoproteins, which assemble in viral
capsids at the cytoplasm (Song et al., 2019). These capsids
then bud into the lumen of endoplasmic reticulum (ER)-Golgi
compartments, where viruses are finally released into the
extracellular space by exocytosis. Potentially, any of these viral
cycle steps could be targeted with antivirals, so we have thus
searched for these compounds as well.
Finally, as the most effective antiviral treatments are usually
based on combined therapies that tackle distinct steps of the viral
life cycle, we also tested the active compounds in combination.
These combinations may be critical to abrogate the potential
emergence of resistant viruses and to increase antiviral activity,
enhancing the chances to improve clinical outcome.
MATERIAL AND METHODS
Cell Cultures
Vero E6 cells (ATCC CRL-1586) were cultured in Dulbecco’s
modified Eagle medium (DMEM; Lonza) supplemented with 5%
fetal calf serum (FCS; EuroClone), 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM glutamine (all ThermoFisher Scientific).
HEK-293T (ATCC repository) were maintained in DMEM with
10% fetal bovine serum, 100 IU/ml penicillin and 100 μg/ml
streptomycin (all from Invitrogen). HEK-293T overexpressing
the human ACE2 were kindly provided by Integral Molecular
Company and maintained in DMEM (Invitrogen) with 10% fetal
bovine serum, 100 IU/ml penicillin and 100 μg/ml streptomycin,
and 1 μg/ml of puromycin (all from Invitrogen). TMPRSS2
human plasmid (Origene) was transfected using
X-tremeGENE HP Transfection Reagent (Merck) on HEK-
293T overexpressing the human ACE2 and maintained in the
previously described media containing 1 mg/ml of geneticin
(Invitrogen) to obtain TMPRSS2/ACE2 HEK-293T cells.
Virus isolation, Titration and Sequencing
SARS-CoV-2 was isolated from a nasopharyngeal swab
collected from an 89-year-old male patient giving informed
consent and treated with Betaferon and hydroxychloroquine for
2 days before sample collection. The swab was collected in 3 ml
medium (Deltaswab VICUM) to reduce viscosity and stored at
−80°C until use. Vero E6 cells were cultured on a cell culture
flask (25 cm2) at 1.5 x 106 cells overnight prior to inoculation
with 1 ml of the processed sample, for 1 h at 37°C and 5% CO2.
Afterward, 4 ml of 2% FCS-supplemented DMEMwere supplied
and cells were incubated for 48 h. Supernatant was harvested,
centrifuged at 200 × g for 10 min to remove cell debris and
stored at −80°C. Cells were assessed daily for cytopathic effect
and the supernatant was subjected to viral RNA extraction and
specific RT-qPCR using the SARS-CoV-2 UpE, RdRp and N
assays (Corman et al., 2020). The virus was propagated for two
passages and a virus stock was prepared collecting the
supernatant from Vero E6.
Viral RNA was extracted directly from the virus stock using
the Indimag Pathogen kit (Indical Biosciences) and transcribed to
cDNA using the PrimeScript™ RT reagent Kit (Takara) using
oligo-dT and random hexamers, according to the manufacturer’s
protocol. DNA library preparation was performed using SWIFT
amplicon SARS-CoV-2 panel (Swift Biosciences). Sequencing
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ready libraries where then loaded onto Illumina MiSeq platform
and a 300 bp paired-end sequencing kit. Sequence reads were
quality filtered and adapter primer sequences were trimmed using
trimmomatic. Amplification primer sequences were removed
using cutadapt (Martin, 2011). Sequencing reads were then
mapped against coronavirus reference (NC_045512.2) using
bowtie2 tool (Langmead and Salzberg, 2012). Consensus
genomic sequence was called from the resulting alignment at a
18 × 1800 × 879 average coverage using samtools (Li et al., 2009).
Genomic sequence was deposited at GISAID repository (http://
gisaid.org) with accession ID EPI_ISL_510689.
Pseudovirus Production
HIV-1 reporter pseudoviruses expressing SARS-CoV-2 Spike
protein and luciferase were generated using two plasmids. pNL4-
3. Luc.R-E-was obtained from the NIH AIDS repository. SARS-
CoV-2. SctΔ19 was generated (Geneart) from the full protein
sequence of SARS-CoV-2 spike with a deletion of the last 19
amino acids in C-terminal, human-codon optimized and
inserted into pcDNA3.4-TOPO (Ou et al., 2020b). Spike plasmid
was transfected with X-tremeGENE HP Transfection Reagent
(Merck) into HEK-293T cells, and 24 h post-transfection, cells
were transfected with pNL4-3. Luc.R-.E-. Supernatants were
harvested 48 h later, filtered with 0.45 µM (Millex Millipore) and
stored at −80°C until use. Control pseudoviruses were obtained by
replacing the spike plasmid by a VSV-G plasmid (kindly provided
by Dr Andrea Cimarelli). The p24gag content of all viruses was
quantified using an ELISA (Perkin Elmer) and viruses were titrated
in HEK-293T overexpressing the human ACE2.
Antivirals and Compounds
The complete list of compounds used for this study and vendors
are shown in Supplementary Tables S1–S5. Drugs were used at
concentrations ranging from 100 μM to 0.0512 nM at 5-fold serial
dilutions. NPOs were used at concentrations ranging from 10 μM
to 0.00512 nM at 5-fold serial dilutions. Plitidepsin was also
assayed at concentrations ranging from 10 μM to 0.5 nM at 3-
fold dilutions. Interferons were assayed at concentrations ranging
from 104 to 0.0005 IU/ml at 5-fold serial dilutions. When two
drugs were combined, each one was added at a 1:1 molar ratio at
concentrations ranging from 100 μM to 0.0512 nM at 5-fold serial
dilutions. In combination with other drugs, plitidepsin was also
assayed at concentrations ranging from 10 μM to 0.5 nM at 3-fold
dilutions.
Antiviral Activity
Increasing concentrations of antiviral compounds were added to
Vero E6 cells and immediately after, we added 101.8 TCID50/mL
of SARS-CoV-2, a concentration that achieves a 50% of cytopathic
effect (20 TCID50 per well to 30,000 cells in 200 µl). Untreated
non-infected cells and untreated virus-infected cells were used as
negative and positive controls of infection, respectively. To detect
any drug-associated cytotoxic effect, Vero E6 cells were equally
cultured in the presence of increasing drug concentrations, but in
the absence of virus. Cytopathic or cytotoxic effects of the virus or
drugs were measured 3 days after infection, using the CellTiter-
Glo luminescent cell viability assay (Promega). Luminescence was
measured in a Fluoroskan Ascent FL luminometer (ThermoFisher
Scientific).
IC50 Calculation and Statistical Analysis
Response curves of compounds or their mixes were adjusted to a
non-linear fit regression model, calculated with a four-parameter
logistic curve with variable slope. Cells not exposed to the virus
were used as negative controls of infection, and were set as 100%
of viability to normalize data and calculate the percentage of
cytopathic effect. Statistical differences from 100% were assessed
with a one sample t test. All analyses and figures were generated
with the GraphPad Prism v8.0b Software.
In Silico Drug Modeling
We performed Glide docking on SARS-CoV-2 3CL Main
protease using the DrugBank database (https://go.drugbank.
com), with a total of 6837 molecules containing FDA approved
drugs, reported phased I/II/III drugs and experimental
molecules (i.e. drugs that are at the preclinical or animal
testing stage) (Gupta and Zhou, 2020). For this, two
different receptors were prepared, the 6LU7 pdb structure,
after removing the covalently bound inhibitor, and a
combination of two crystals from the Diamond collection
(https://www.diamond.ac.uk/covid-19). This combination
intended to open a bit more the active site by rotating
Gln189 and exposing it more to the solvent, after visual
inspection of the different fragment crystals. Receptors were
prepared with the Schrodinger’s protein wizard assigning
protonation states at pH 7 using the interactive optimizer.
Also, after inspection of the recent crystal structures, Glide
SP docking was performed with two different (ligand)
hydrogen bond constraints: Glu16 and His163 (this last
residue with epsilon protonation); we enforced single
constraints and also attempted the combination of both. The
best 11 molecules, based on Glides’s docking score, were
selected for experimental validation. Notice, however, that
top docking scores, did not exceed −9, indicating poor
potential binding, in agreement with other non-productive
repurposing efforts reported on SARS-CoV-2 main protease,
including sophisticated in silico studies (Gupta and Zhou,
2020).
Pseudovirus Assay
HEK-293T overexpressing the human ACE2 and TMPRSS2
were used to test antivirals at the concentrations found to be
effective for SARS-CoV-2 without toxicity, which were the
following: 5 µM for niclosamide; 10 µM for chloroquine,
chlorpromazine, ciclesonide, MDL 28170 and fenofibrate;
20 µM for hydroxychloroquine, CA-074-Me and arbidol HCl;
25 µM for E-64d; 50 µM for Baricitinib; 100 µM for
Amantadine, NB-DNJ, 3’ sialyl-lactose Na salt, tofacitinib,
and Camostat mesylate; 1000 µM for methyl-β-cyclodextrin,
and 12,5 mg/ml for AAT. A constant pseudoviral titer was
used to pulse cells in the presence of the drugs. At 48 h post-
inoculation, cells were lysed with the Glo Luciferase system
(Promega). Luminescence was measured with an EnSight
Multimode Plate Reader (Perkin Elmer).
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FIGURE 1 | Antiviral activity of entry inhibitors against SARS-CoV-2. (A) Antiviral activity of hydroxychloroquine and azithromycin. Cytopathic effect on Vero E6 cells
exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of hydroxychloroquine, azithromycin, and their combination. Drugs were
used at a concentration ranging from 0.0512 nM to 100 µM. When combined, each drug was added at the same concentration. Non-linear fit to a variable response
curve from one representative experiment with two replicates is shown (red lines), excluding data from drug concentrations with associated toxicity. The particular
IC50 value of this graph is indicated. Cytotoxic effect on Vero E6 cells exposed to increasing concentrations of drugs in the absence of virus is also shown (grey lines). (B)
Cytopathic effect on Vero E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of amantadine, a clathrin-mediated
(Continued )
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SARS-CoV-2 Detection in the Supernatant
of Infected Cells
Viral accumulation in the supernatant of Vero E6 cells infected as
described previously in the presence of increasing concentrations
of the indicated antiviral compounds was measured at day 3 post-
infection. The amount of SARS-CoV-2 nucleoprotein released to
the supernatant was measured with an ELISA (SinoBiologicals),
according to the manufacturer’s protocol. This ELISA contains a
buffer to lyse viral membranes and release nucleoprotein content.
RESULTS
We have tested the antiviral activity of different clinically
available compounds and their combinations by assessing their
ability to inhibit viral induced cytopathic effect in vitro. Our
strategy was circumscribed mostly to compounds approved for
clinical use, since they are ideal candidates for entering into fast
track clinical trials. Drug selection criteria first focused on
compounds already being tested in clinical trials, along with
well-known human immunodeficiency virus-1 (HIV-1) and
hepatitis C virus (HCV) inhibitors, as well as other
compounds suggested to have potential activity against SARS-
CoV-2 in molecular docking analysis or in vitro assays (Chen
et al., 2020a; Dittmar et al., 2020; Ianevski et al., 2020; Riva et al.,
2020; Weston et al., 2020).
We first assessed the activity of 16 compounds with
hypothetical capacity to inhibit viral entry, and then we
focused on 22 drugs thought to block viral replication upon
SARS-CoV-2 fusion. Molecular docking studies provided an
additional 11 candidates, which were predicted to inhibit the
SARS-CoV-2 main protease. Finally, 23 compounds with
unknown mechanism of action were also assessed. By these
means, we have compared 72 drugs and 28 of their
combinations for their capacity to counteract SARS-CoV-2-
induced cytopathic effect in vitro.
Antiviral Activity of Compounds that
Potentially Inhibit Viral Entry
We first tested compounds that could have an effect before viral
entry by impairing virus-cell fusion (Supplementary Table S1).
We confirmed the inhibitory effect of hydroxychloroquine
against SARS-CoV-2-induced cellular cytotoxicity on Vero E6
cells (Liu et al., 2020). As shown in Figure 1A, this drug was able
to inhibit viral-induced cytopathic effects at concentrations where
no cytotoxic effects of the drug were observed, as previously
reported (Liu et al., 2020; Wang et al., 2020). Since
hydroxychloroquine was first administered in combination
with the antibiotic azithromycin (Gautret et al., 2020), which
induces antiviral responses in bronchial epithelial cells (Gielen
et al., 2010), we tested this antibiotic alone and in combination
(Figure 1A), but found a similar activity to that of the
chloroquine derivative alone (Figure 1A). Indeed, this was
also the case when we tested hydroxychloroquine in
combination with different HIV-1 protease inhibitors and
other relevant compounds currently being tested in clinical
trials (Supplementary Table S2).
Additional Food and Drug Administration (FDA)-approved
compounds previously used to abrogate viral entry via clathrin-
mediated endocytosis such as amantadine or chlorpromazine
were also tested in this SARS-CoV-2-induced cytotoxicity assay
(Supplementary Table S2). Yet, we did not find any prominent
effect of these agents; only a partial inhibition at 100 μM for
amantadine (Figure 1B). The broad cathepsin B/L inhibitor E64-
d also showed partial inhibitory activity (Figure 1B). E64-d exerts
activity against viruses cleaved by cellular cathepsins upon
endosomal internalization, as previously described using
pseudotyped SARS-CoV-2 (Hoffmann et al., 2020). While
these results could not be confirmed using the specific
cathepsin B inhibitor CA-074-Me due to drug-associated
toxicity (Supplementary Table S1), none of these cathepsin
inhibitors is approved for clinical use. It has also been
suggested that hydroxychloroquine could block SARS-CoV-2
spike interaction with GM1 gangliosides (Fantini et al., 2020).
GM1 gangliosides are enriched in cholesterol domains of the
plasma membrane and have been previously shown to bind to
SARS-CoV spike protein (Lu et al., 2008). This mode of viral
interaction is aligned with the capacity of methyl-beta
cyclodextrin, which depletes cholesterol from the plasma
membrane to abrogate SARS-CoV-2 induced cytopathic effect
(Figure 1B), as previously reported for SARS-CoV (Lu et al.,
2008). Removal of cholesterol redirected ACE2 receptor to other
domains, but did not alter the expression of the viral receptor (Lu
et al., 2008). Moreover, NB-DNJ, an inhibitor of ganglioside
biosynthesis pathway, also decreased SARS-CoV-2 cytopathic
FIGURE 1 | endocytosis inhibitor, E-64d, a pan-cathepsin inhibitor acting downstream once viruses are internalized in endosomes, NB-DNJ, an inhibitor of ganglioside
biosynthesis and methyl-β-cyclodextrin, a cholesterol-depleting agent. All drugs were used at a concentration ranging from 0.0512 nM to 100 µM aside from methyl-
β-cyclodextrin, which was used 10 times more concentrated. Non-linear fit to a variable response curve from one experiment with two replicates is shown (red lines).
Cytotoxic effect on Vero E6 cells exposed to increasing concentrations of drugs in the absence of virus is also shown (grey lines). (C) Cytopathic effect on Vero E6 cells
exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of camostat, a TMPRSS2 inhibitor, and ATT, an alpha-1 antyitrypsin, a
broad cellular protease inhibitor, as described in (A). (D) Effect of entry inhibitors on luciferase expression of reporter lentiviruses pseudotyped with SARS-CoV-2 Spike in
ACE2 expressing HEK-293T cells. Values are normalized to luciferase expression by mock-treated cells set at 100%. Mean and s.e.m. from two experiments with one to
three replicates. Cells were exposed to fixed amounts of SARS-CoV-2 Spike lentiviruses in the presence of a non-toxic constant concentration of the drugs tested on
Vero E6. Significant statistical deviations from 100% were assessed with a one sample t test. (E) Comparison of entry inhibitors blocking viral endocytosis, such as
chloroquine, with inhibitors blocking serine protease TMPRSS2 expressed on the cellular membrane, such as camostat, on different cell lines. ACE2 expressing HEK-
293T cells transfected or not with TMPRSS2 were exposed to SARS-CoV-2 Spike lentiviruses as described in (B). Values are normalized to luciferase expression by
mock-treated cells set at 100%. Mean and s.e.m. from at least two representative experiments with two replicates. Statistical deviations from 100%were assessed with
a one sample t test.
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effect (Figure 1B). These results highlight the possible role of
gangliosides in viral binding, although in soluble competition the
polar head group of GM3 ganglioside (3’ Sialyllactose) was not
able to reduce viral-induced cytopathic effect (Supplementary
Table S1). Of note, previously reported antiviral agents such as
the autophagy BECN1-stabilizing compounds niclosamide or
ciclesonide (Gassen et al., 2020), (Jeon et al., 2020), the
membrane lipid intercalating compound arbidol (Haviernik
et al., 2018) and the two JAK inhibitors baricitinib and
tofacitinib (Richardson et al., 2020; Stebbing et al., 2020) failed
to protected Vero E6 cells from SARS-CoV-2 induced cytopathic
effect (Supplementary Table S1). We next tested camostat, a
serine protease inhibitor with capacity to abrogate SARS-CoV-2
Spike priming on the plasma membrane of human pulmonary
cells and avoid viral fusion (Hoffmann et al., 2020). Camostat
showed no antiviral effect on Vero E6 cells (Figure 1C), what
indicates that the alternative viral endocytic route is the most
prominent entry route in this renal cell type. A broader cellular
protease inhibitor such as alpha-1 antitrypsin (AAT), used to
treat severe AAT human deficiency and currently under clinical
study for COVID-19 due to its anti-inflammatory potential, has
already shown capacity to limit SARS-CoV-2 entry in cells
expressing TMPRSS2 (Münch, 2020; Oguntuyo et al., 2020).
When we tested AAT antiviral efficacy on Vero E6, AAT
exerted an effect but required high concentrations that will
most likely rely on the activity of these proteases in the
endosomal route (Figure 1C).
To confirm that identified compounds listed in
Supplementary Table S1 specifically inhibit the viral entry
step, we employed a luciferase-based assay using
pseudotyped lentivirus expressing the spike protein of
SARS-CoV-2, which allows to detect viral fusion on HEK-
293 T cells transfected with ACE2. As a control, we used
lentiviruses pseudotyped with a VSV glycoprotein, where no
entry inhibition above 20 % was detected for any of the drugs
tested (data not shown). In sharp contrast, SARS-CoV-2
pseudoviruses were effectively blocked by most of the drugs
previously tested on Vero E6 with wild-type virus (Figure 1D).
The main differences were observed with CA-074-Me,
ciclesonide and arbidol. These compounds showed a partial
blocking effect on ACE2 HEK-293T cells that was not obvious
when using replication competent SARS-CoV-2 on Vero E6
(Supplementary Figure S1). In addition, NB-DNJ failed to
block viral entry (Figure 1D). Overall, using alternative SARS-
CoV-2 viral systems, we could identify chloroquine
derivatives, cathepsin inhibitors and cholesterol depleting
agents as the most promising candidates to block SARS-
CoV-2 endocytosis in Vero E6 and HEK-293T cells
transfected with ACE2. However, chloroquine derivatives
were the only ones that displayed an IC50 below 25 µM
(Table 1), and were also active abrogating pseudoviral entry
into HEK-293 T cells expressing ACE2 (Figure 1E). Although
camostat failed to inhibit viral fusion on ACE2 HEK-293T cells
(Figure 1E), its activity was rescued when these cells were
transfected with TMPRSS2. The opposite effect was observed
for chloroquine, which reduced its inhibitory activity on
TMPRSS2 transfected cells (Figure 1E). Our results
highlight that alternative routes govern SARS-CoV-2 viral
entry and these pathways vary depending on the cellular
target. Thus, effective treatments may need to block both
plasma membrane fusion and endosomal routes to fully
achieve viral suppression.
Antiviral activity of Compounds that
Potentially Inhibit Post-entry Steps
In our search for antivirals inhibiting post-viral entry steps, we
first focused on remdesivir, which has in vitro activity against
SARS-CoV-2 after viral entry (Wang et al., 2020) and has already
been approved for the treatment of COVID-19 by the FDA and
the European Medicines Agency (EMA). We further confirmed
the in vitro capacity of remdesivir to inhibit SARS-CoV-2-
induced cytopathic effect on Vero E6 (Figure 2A). The IC50
value of this drug in repeated experiments was always below
10 µM (Supplementary Table S2). In combination with
increasing concentrations of hydroxychloroquine, however,
remdesivir did not significantly modified its own antiviral
effect (Figure 2B). This was also the case for other antivirals
tested in combination (Supplementary Table S3). Of note, other
RNA polymerase inhibitors such as galdesivir, which was
proposed to tightly bind to SARS-CoV-2 RNA-dependent
RNA polymerase (Elfiky, 2020), showed no antiviral effect
(Supplementary Table S3). Favipiravir, approved by the
National Medical Products Administration of China as the
first anti-COVID-19 drug in China (Tu et al., 2020), showed
only partial inhibitory activity at the non-toxic concentration of
100 µM (Supplementary Table S3).
We also assessed clinically approved protease inhibitors with
potent activity against HIV-1. However, none of the HIV-1
protease inhibitors detailed in Supplementary Table S3
showed remarkable protective antiviral activity against SARS-
CoV-2 infection on Vero E6 cells, with the exception of
nelfinavir mesylate hydrate, which showed an IC50 value
below 10 µM (Supplementary Table S3 and Figure 2C).
Lopinavir and tipranavir inhibited SARS-CoV-2-induced
cytopathic effect at the non-toxic concentration of 20 μM, and
amprenavir exhibited activity at the non-toxic concentration of
100 µM (Figure 2C). Darunavir, which has been tested in clinical
trials, showed partial inhibitory activity at 100 μM, although this
concentration had 8.5 ± 6.2% of cytotoxicity associated
(Figure 2C). Of note, we tested HIV-1 reverse transcriptase
inhibitors such as tenofovir disoproxil fumarate, emtricitabin,
tenofovir alafenamide, and their combinations, but they also
failed to show any antiviral effect against SARS-CoV-2
(Supplementary Table S1). These results indicate that future
clinical trials should contemplate the limited antiviral effect
displayed by these anti-HIV-1 inhibitors against SARS-CoV-
2 in vitro.
We also assessed the inhibitory capacity of HCV inhibitors,
but none showed any antiviral activity (Supplementary Table
S3). Of note, exogenous interferon-2α and interferon-γ displayed
antiviral activity against SARS-CoV-2 (Supplementary Table
S3). In light of these results, we tested the inhibitory effect of
the TLR 7 agonist vesatolimod that triggers interferon
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production. Although this agonist was not able to protect from
the viral-induced cytopathic effect on Vero E6 (Supplementary
Table S3), as expected since it is an interferon-producer deficient
cell line (Emeny and Morgan, 1979), it could still be useful in
other competent cellular targets. Since severe COVID-19 patients
display impaired interferon responses (Hadjadj et al., 2020), these
strategies may be valuable to avoid disease complication. In
addition, we also assessed several compounds with the best
computational docking scores among approved drugs against
the 3CL protease of SARS-CoV-2, but none of themwere effective
to protect Vero E6 from viral induced cytopathic effect
(Supplementary Table S4).
The most potent antiviral tested was plitidepsin (Figure 2D),
which targets the eukaryotic Elongation Factor 1A2 (eEF1A2)
and has been previously used for the treatment of multiple
myeloma. The mean IC50 value of this drug in repeated
experiments was always in nM concentrations
(Supplementary Table S3). In combination with other active
antivirals, we did not observe a reduction on IC50 values
(Supplementary Table S2). This result indicates no significant
synergy, but also highlights the possibility of using plitidepsin
without reducing its antiviral activity in combined therapies
(Figure 2D), what could be relevant to avoid possible selection
of resistant viruses. Overall, plitidepsin showed the lowest IC50
values of all the compounds tested in this in vitro screening
(Table 1).
Antiviral Activity of Compounds with
Unknown Mechanism of Action
We also assessed the inhibitory capacity of several inhibitors and
broad anti-bacterial, anti-parasitic, anti-malarial, anti-influenza
and anti-fungal compounds, along with other pharmacological
agents previously suggested to interfere with SARS-CoV-2
infection (Supplementary Table S5). Such was the case of
ivermectin, an FDA-approved broad spectrum anti-parasitic
agent previously reported to inhibit the replication of SARS-
CoV-2 in vitro as measured by RNA accumulation (Caly et al.,
2020).
However, among these potential antivirals, only three types
of molecules exerted detectable antiviral activity in our assay:
itraconazole, fenofibrate, and calpain and cathepsin inhibitors
such as MDL 28170 and NPO compounds. Itraconazole, an
antifungal that may interfere with internal SARS-CoV-2
budding within infected cells (Wu et al., 2020), displayed an
IC50 value of 80 µM (Figure 3A and Supplementary Table S5).
Fenofibrate is clinically used to treat dyslipidemia via activation
of PPARα, and also inhibited the cytopathic effect exerted by
SARS-CoV-2 on Vero E6 at 20 µM (Figure 3B and
Supplementary Table S5). As fenofibrate is a regulator of
cellular lipid metabolism, we made use of the luciferase-
based viral entry assay to try to elucidate its mode of action.
When lentiviruses pseudotyped with the spike protein of SARS-
CoV-2 were added to ACE2-expressing HEK-293 T cells in the
presence of fenofibrate, viral entry was abrogated (Figure 3C).
The most potent agent found was MDL 28170, a calpain III
inhibitor in a pre-clinical stage of development that displayed
activity in the nanomolar range (Figure 3D and
Supplementary Table S5), as previously identified in vitro
(Riva et al., 2020). Moreover, three out of four different
calpain and cathepsin inhibitors named NPO showed potent
antiviral activity too (Supplementary Figure S2). Of note, in
combination with other active antivirals, we did not observe a
reduction on IC50 values of MDL 28170 (Supplementary
Table S2).
Inhibitors of calpains, which are cysteine proteases, might
impair the activity of viral proteases like 3CL (main protease)
and PLpro (papain-like protease) (Schneider et al., 2012; Riva
et al., 2020). However, calpain inhibitors may also inhibit
TABLE 1 | Compounds with antiviral activity ordered depending on their IC50 values on Vero E6. Notice that plitidepsin and cathepsin inhibitors display IC50 values in the nM
range, while the rest of the compounds are in the µM or 102 IU/ml range.
Drug IC50/CC50 μM
(Mean +/− SD)
Mode of action Previous clinical
use
Vendor Origin
nM Plitidepsin 0.06 +/− 0.02/> 0.1 Targets eukaryotic Elongation Factor 1A2
(eEF1A2)
Multiple myeloma PharmaMar
MDL 28170 0.14 +/− 0.06/> 87 Calpain III and Cathepsin B inhibitor Pre-clinical Merck
NPO-2142; -2143
and-2260
∼0.54/>10 Calpain and Cathepsin Inhibitors Pre-clinical Landsteiner
Genmed
Remdesivir 2.16 +/− 4.1/> 85 RNA Polymerase inhibitor Ebola virus Cayman
Chemical
Hydroxycloroquine 10.9 +/− 11.3/> 96 Clathrin-mediated endocitosys or pH-







Not calculated, but active < 10/
> 25
Protease inhibitor HIV-1 Sigma Aldrich
Chloroquine 3.86/>25 Clathrin-mediated endocitosys or pH-
dependent viral fusion inhibitor
Malaria Sigma Aldrich
Interferon-2α 8.1+/−0.7 × 102 IU/mL/> 100
× 102 IU/mL
IFN stimulated antivirus proteins Hepatitis and HIV-1 Sigma Aldrich
interferon-γ 11.2 × 102 IU/mL/> 100 ×
102 IU/mL
IFN stimulated antivirus proteins Granulomatous
disease
Sigma Aldrich
Fenofibrate 19.8 +/− 8/>100 Activates PPARα Dyslipidemia Lacer
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cathepsin B-mediated processing of viral spike proteins or
glycoproteins, including SARS-CoV and Ebola (Schneider
et al., 2012; Zhou and Simmons, 2012). To understand the
mechanisms of action of calpain and cathepsin inhibitors
such as MDL 28170, we added lentiviruses pseudotyped with
the spike protein of SARS-CoV-2 to ACE2-expressing HEK-
293T cells and the same cells also expressing TMPRSS2 in the
presence of this drug. Importantly, MDL 28170 only blocked
viral entry in ACE2-expressing cells (Figure 3E). This result
indicates that MDL 28170 blocks cathepsins that are
implicated in SARS-CoV-2 entry via the alternative
endosomal pathway, as described for chloroquine
derivatives and E-64d (Figure 3E), which are all active
when TMPRSS2 is not present and their inhibitor camostat
displays no activity (Figure 3E).
In conclusion, among the 72 compounds and their 28
combinations tested herein for their potential capacity to abrogate
SARS-CoV-2 cytopathic effect, we only found 13 compounds with
antiviral activity including camostat, and only eight types of these
drugs had an IC50 below 25 µM or 10
2 IU/ml (Table 1). These eight
families of compounds were able to abrogate SARS-CoV-2 release to
the supernatant in a dose dependent manner (Figure 4), indicating
that the reduction in the cytopathic effect that we had measured in
cells correlates with viral production. In the case of fenofibrate,
however, this compound was less active inhibiting viral release as
compared to the rest of the inhibitors tested (Figure 4), while still
preserved cells from viral induced -cytopathic effect. As the eight
families of compounds found tackle different steps of the viral life
cycle, they could be tested in combined therapies to abrogate the
potential emergence of resistant viruses.
FIGURE 2 | Antiviral activity of post-entry inhibitors. (A) Cytopathic effect on Vero E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of
increasing concentrations of Remdesivir. Drug was used at a concentration ranging from 0.0512 nM to 100 μM. Non-linear fit to a variable response curve from one
representative experiment with two replicates is shown (red lines), excluding data from drug concentrationswith associated toxicity. The particular IC50 value of this graph
is indicated. Cytotoxic effect on Vero E6 cells exposed to increasing concentrations of drugs in the absence of virus is also shown (grey lines). (B). Cytopathic effect
on Vero E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of remdesivir and its combination with
hydroxychloroquine, as detailed in (A). Drugs in combination were used at a concentration ranging from 0.0512 nM to 100 μM (left panel). (C). Cytopathic effect on Vero
E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of protease inhibitors against HIV-1. Nelfinavir mesylate hydrate
was the only drug with activity. Inhibitors were used at a concentration ranging from 0.0512 nM to 100 μM. The particular IC50 value of this graph is indicated (D).
Cytopathic effect on Vero E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of plitidepsin and its combinations with
hydroxychloroquine and remdesivir. When combined, each drug was added at the same concentration. Drugs were used at a concentration ranging from 0.5 nM to 10
μM. The particular IC50 value of these graphs is indicated.
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FIGURE 4 | Decreased release of SARS-CoV-2 in the presence of inhibitors with antiviral activity. (A). Viral release to the supernatant in the presence of the
indicated compounds added at increasing concentrations 3 days post-infection of Vero E6 cells. SARS-CoV-2 nucleoprotein was detected with an ELISA at
concentrations were drugs were nontoxic. Mean and s.e.m. from two experiments. (B). Viral release to the supernatant in the presence of the indicated interferons as
described in A. Mean and s.e.m. from one experiment.
FIGURE 3 | Antiviral activity of inhibitors with unknown mechanism of action. (A). Cytopathic effect on Vero E6 cells exposed to a fixed concentration of
SARS-CoV-2 in the presence of increasing concentrations of Itraconazole. Drug was used at a concentration ranging from 0.0512 nM to 100 µ. Non-linear fit to a
variable response curve from one representative experiment with two replicates is shown (red lines), excluding data from drug concentrations with associated toxicity.
The particular IC50 value of this graph is indicated. Cytotoxic effect on Vero E6 cells exposed to increasing concentrations of drugs in the absence of virus is also
shown (grey lines). (B). Cytopathic effect on Vero E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing concentrations of Fenofibrate,
as detailed in (A). (C). Effect of fenofibrate on the entry of luciferase expressing lentiviruses pseudotyped with SARS-CoV-2 Spike in ACE2-expressing HEK-293T cells.
Values are normalized to luciferase expression by mock-treated cells set at 100%. Mean and s.e.m. from two experiments with two replicates. Statistical deviations from
100% were assessed with a one sample t test. (D). Cytopathic effect on Vero E6 cells exposed to a fixed concentration of SARS-CoV-2 in the presence of increasing
concentrations of MDL 28170, as detailed in (A). (E). Comparison of MDL 28170 activity with entry inhibitors blocking viral endocytosis, such as chloroquine and E-64d,
and inhibitors blocking serine protease TMPRSS2, such as camostat. ACE2 expressing HEK-293T cells transfected or not with TMPRSS2were exposed to SARS-CoV-
2 Spike lentiviruses in the presence of these compounds. Values are normalized to luciferase expression by mock-treated cells set at 100%. Mean and s.e.m. from at
least two experiments with two replicates. Statistical deviations from 100% were assessed with a one sample t test.
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DISCUSSION
We have assessed the anti-SARS-CoV-2 activity of clinically
approved compounds that may exert antiviral effect alone or
in combination. Although we were not able to detect any
remarkable synergy in vitro, further work in more
physiological cellular models is needed to address if any
synergism and additivity can be found between identified
compounds. Combined therapies are key to tackle viral
infections and to reduce the appearance of viral resistance,
and that is why identifying synergism and antagonism for
SARS-CoV-2 antivirals is of key importance (Bobrowski et al.,
2020). We have tested more than seventy compounds and their
combinations, and verified a potent antiviral effect of
hydroxychloroquine and remdesivir, along with plitidepsin,
cathepsin and calpain inhibitors MDL 28170 and NPO,
nelfinavir mesylate hydrate, interferon-2α, interferon-γ and
fenofibrate. These are therefore the most promising agents
found herein that were able to protect cells from viral-induced
cytopathic effect by preventing viral replication.
Our findings highlight the utility of using hydroxychloroquine
and MDL 28170 or other cathepsin inhibitors to block viral entry
via the endosomal pathway in kidney cell lines such as Vero E6 or
HEK-293T. However, the endosomal viral entry route is absent in
pulmonary cells (Maisonnasse et al., 2020) and, therefore,
camostat should be considered as the primary inhibitor to
limit SARS-CoV-2 entry in pulmonary tissues or in cells
expressing TMPRSS2 (Hoffmann et al., 2020). These findings
can explain why randomized clinical trials using
hydroxychloroquine have failed to show a significant
protective effect (Boulware et al., 2020; Cavalcanti et al., 2020).
Nonetheless, in combined therapies, it should be noted that
agents targeting the alternative endosomal SARS-CoV-2 entry
route such as hydroxychloroquine or MDL 28170 could be key to
stop viral dissemination in other extrapulmonary tissues where
viral replication has been already detected (Hanley et al., 2020),
and viral entry could take place through this endosomal pathway.
This could partially explain why in a retrospective observational
study including more than 2500 patients, hydroxychloroquine
treatment showed a significant reduction of in-hospital mortality
(Arshad et al., 2020). Thus, since alternative routes govern SARS-
CoV-2 viral entry depending on the cellular target (Ou et al.,
2020a), effective treatments might be needed to block both
plasma membrane fusion and endosomal entry to broadly
achieve viral suppression.
SARS-CoV-2 replication could be effectively blocked using
nelfinavir mesylate hydrate, remdesivir and plitidepsin. While
nelfinavir showed lower potency, remdesivir and plitidepsin were
the most potent agents identified. However, remdesivir and
plitidepsin are not yet suitable for oral delivery and require
intravenous injection, complicating their clinical use for
prophylaxis. Finally, we also confirmed the antiviral effect of
type I and II interferons as well as fenofibrate, which have been
extensively used in the clinic for many years and may therefore
prove valuable for therapeutic use.
The data presented herein should be interpreted with caution,
as the IC50 values of drugs obtained in vitro may not reflect what
could happen in vivo upon SARS-CoV-2 infection. The best
antiviral compounds found in the present study need to be
tested in adequate animal models. This strategy already helped
to confirm the activity of remdesivir against SARS-CoV-2
(Williamson et al., 2020), while also questioning the use of
hydroxychloroquine in monotherapy (Maisonnasse et al., 2020).
Thus, assessing antiviral activity and safety in animal models is key
to identify and advance those compounds with the highest
potential to succeed in upcoming clinical trials. In turn, in vitro
results confirmed in animal models will provide a rational basis to
perform future clinical trials not only for treatment of SARS-CoV-
2-infected individuals, but also for pre-exposure prophylaxis
strategies that could avoid novel infections. Prophylaxis could
be envisioned at a population level or to protect the most
vulnerable groups, and should be implemented until an
effective vaccine is developed. In particular, orally available
compounds with proven safety profiles, such as fenofibrate,
could represent promising agents.
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